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ABSTRACT 
BACKGROUND: The wireless motility capsule (WMC) offers the ability to investigate 
luminal gastrointestinal (GI) physiology in a minimally invasive manner.  
 
AIMS: To investigate the effect of testing protocol, gender, age and study country on 
regional GI transit times and associated pH values using the WMC.  
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METHODS: Regional GI transit times and pH values were determined in 215 healthy 
volunteers from USA and Sweden studied using the WMC over a 6.5-year period. The 
effects of test protocol, gender, age and study country were examined. 
 
RESULTS: For GI transit times, testing protocol was associated with differences in 
gastric emptying time (shorter with protocol 2: median difference: 52 min, p=0.0063) 
and colonic transit time (longer with protocol 2: median 140 min, p=0.0189), but had 
no overall effect on whole gut transit time. Females had longer gastric emptying time 
(by median 17 min, p=0.0307), and also longer colonic transit time (104 min, 
p=0.0285) and whole gut transit time (263 min, p=0.0077). Increasing age was 
associated with shorter small bowel transit time (p=0.002), and study country also 
influenced small bowel and colonic transit times. Whole gut and colonic transit times 
showed clustering of data at values separated by 24 hours, suggesting that 
describing these measures as continuous variables is invalid. Testing protocol, 
gender and study country also significantly influenced pH values. 
 
CONCLUSIONS: Regional GI transit times and pH values, delineated using the WMC, 
vary based on testing protocol, gender, age and country. Standardisation of testing is 
crucial for cross-referencing in clinical practice and future research. 
 
INTRODUCTION 
Functional gastrointestinal disorders (FGIDs) are prevalent and constitute a 
considerable socioeconomic and healthcare burden 
1, 2
. In patients refractory to 
standard therapeutic interventions, the diagnostic approach may involve using 
specialised tests of gastrointestinal (GI) function 
3
. The assessment of GI transit is 
widely employed, and abnormalities of regional (i.e. stomach, small bowel, large 
bowel) transit are frequently identified 
3, 4
. As FGIDs of the upper and lower GI tract 
commonly co-exist, and symptoms originating from one part of the gut may overlap 
with those from another, localisation of the transit abnormality is now recognised as 
a critical facet in deciding clinical management of complicated FGIDs 
5
. Until recently, 
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the investigations available for the evaluation of GI transit have primarily been 
radiological, with measures generally limited to a single GI region. Given that some 
patients with FGIDs are suspected to have a pan-enteric dysmotility 
6
, a complete, 
and also regional GI profile is therefore desirable in delineating pathophysiology and 
guiding subsequent management. As a ‘stand-alone’ test, only scintigraphy has been 
available for the assessment of regional GI transit, but its access is generally limited 
to specialist centers and entails prolonged periods of imaging and multiple visits to 
the investigation facility 
7
. As an alternative, an ingestible, telemetric device (the 
wireless motility capsule: WMC) is now commercially available, enabling the 
measurement of both regional and total GI transit times 
8
 in a minimally-invasive 
manner without recourse to the use of radiation.  
 
For a clinical investigation to be considered useful, its endpoint, by necessity, must 
be able to distinguish abnormality from normality. Thus, robust and reproducible 
normal ranges need to be defined but also need to be finessed by an appreciation of 
the factors that may influence such ranges. Unfortunately, for the majority of 
contemporaneous GI transit tests, normal ranges are largely derived from relatively 
small cohorts with little or no adjustment for specific testing protocol, age or gender 
distribution, see Table 1. For example, the largest published data set of normal 
values of small bowel transit, as defined by radionuclide scintigraphy, is derived from 
only 66 individuals 
9
. While gastric emptying time (GET) has recently been studied in 
a much larger cohort of 319 healthy subjects, the method published involved the use 
of a non-ambulatory, nuclear medicine technique
10
, requiring the patient to be 
present within a hospital radiology facility throughout the investigation. Moreover, 
in most cases, methods are not standardised. For instance, for radio-opaque marker 
(ROM) studies (the most accepted test of whole gut or colonic transit), in excess of 
10 different testing protocols have been published 
11
. 
 
The WMC allows the delineation of regional transit from stereotypical, physiologic 
pH ‘landmarks’ recorded as it traverses the GI tract. Our primary aim was to evaluate 
the effect of testing protocol, gender, age and study country on gastric, small bowel, 
colonic and whole gut transit times in a large cohort of healthy volunteers. With 
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regard to the measurement of pan-GI pH, its absolute utility, beyond landmark 
definition, remains unclear. Differences related to transit and perturbations of the 
microbiota are, to date, hypothetical. Accordingly, our secondary aim was to 
establish normative data for regional GI pH values.  
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Type of Investigation 
Sample 
Size 
Region of 
investigation 
Reference 
Radio-opaque markers 192 WGTT, CTT 
12
 
Radio-opaque markers 43 WGTT 
13
 
Radio-opaque markers 148 CTT 
14
 
Radio-opaque markers 82 CTT 
15
 
Radio-opaque markers 51 CTT 
16
 
Radionuclide scintigraphy 319 GET 
10
 
Radionuclide scintigraphy 123 GET 
17
 
Radionuclide scintigraphy 66 GET, SBTT 
9
 
Radionuclide scintigraphy 90 GET 
18
 
Radionuclide scintigraphy 9 GET, SBTT, CTT, WGTT 
19
 
Combined radio-opaque 
markers and fluoroscopy 
83 GET, SBTT, CTT, WGTT 
20
 
Paracetamol absorption 
test 
9 GET 
21
 
13
C octanoic acid Breath 
Test 
129 GET 
22
 
13
C octanoic acid Breath 
Test 
21 WGTT 
23
 
Real-time ultrasonography 19 GET 
24
 
 
Table 1 – Summary of the major studies describing gastrointestinal regional transit 
times. GET: gastric emptying time; SBTT: small bowel transit time; CTT: colonic transit 
time; WGTT: whole gut transit time. 
 
 
 
MATERIALS & METHODS 
STUDY POPULATION 
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The study population comprised of healthy volunteers who underwent a WMC test 
during the period March 2005 to November 2011. Data from studies performed in 
the USA were supplied by the SmartPill Corporation (JRS), and from studies carried 
out in Sweden by the principal investigator (PMH). In total, data from 231 studies 
were available: 191 performed in the USA, and 40 in Sweden. The data acquired in 
the USA were primarily derived from 2 multi-center clinical trials 
25, 26
; further 
information on subjects acting as controls for a study of gastric emptying in 
gastroparetic patients 
25
, and volunteers involved in a trial studying colonic and 
whole gut transit in constipated patients 
26
 have been published, in part, elsewhere. 
The respective Institutional Review Boards or Ethics Committees at the participating 
sites approved all studies contained herein. 
 
Subjects from the USA were screened with the Mayo GI disease questionnaire 
27
 and 
subjects from Sweden were screened with the Rome III questionnaire for detection 
of FGIDs (translated to Swedish) 
28
 and the Gastrointestinal Symptom Rating Scale 
(GSRS) 
29
 to exclude those with significant symptoms or a history of previous GI 
surgery, except uncomplicated appendectomy and/or laparoscopic cholecystectomy. 
Other general inclusion criteria were: aged >18 or <80 years; absence of 
cardiovascular, endocrine, renal or chronic disease; average bowel movement 
frequency of at least once per 48 hours; no pregnancy (specifically excluded on 
testing if the pregnancy status was equivocal); no other surgery within the past 3 
months; no clinical evidence of diverticulitis, as evidenced by the absence of chronic 
or acute abdominal pain; no medications that could influence GI motility; no tobacco 
use within 8 hours before and after capsule ingestion; no alcohol use 24 hours 
before capsule ingestion and during the monitoring period; body mass index (BMI) 
<35 kg/m
2
. All volunteers gave written informed consent prior to enrolment.  
 
WIRELESS MOTILITY CAPSULE  
The wireless motility capsule (previously SmartPill Corporation, Buffalo, USA; now 
Medtronic, Minneapolis, MN, USA) has been described in detail elsewhere 
25, 26, 30
. In 
brief, the WMC is a single-use cylindrical capsule, measuring 26.8 x 11.7 mm housing 
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a solid-state pressure sensor (range 0 – 350 mmHg), a pH-sensing ion selective field 
effect transistor (range 0.5 – 9 pH units), a solid-state temperature sensor (range 25 
– 49°C), and two silver oxide batteries, which provide a minimum of 5 days 
operational use. Following ingestion, the WMC monitors pressure activity, intra-
luminal pH, and temperature change synchronously as it traverses the GI tract. 
Measurements are transmitted from the capsule at 434 MHz to a data receiver, 
which can be worn on a belt, a harness, or placed near to the subject under study. All 
received data are stored within the data receiver, which has a minimum battery life 
of 7 days. The pH is accurate to within +/- 0.5 units and pressure measurements are 
accurate to +/- 5 mmHg below 100 mmHg. After completion of the study, data can 
be downloaded from the receiver to a compatible computer, via a USB docking 
station, for subsequent display and analysis using proprietary software (MotiliGI; 
Medtronic). 
 
 
STUDY PROTOCOL 
Subjects attended following an overnight fast. Before ingestion, the WMC was 
activated and calibrated. Two different study protocols were used: in meal protocol 
1, subjects ingested the WMC with 50 ml of water followed by an “egg beater” meal, 
which consisted of a scrambled egg substitute mixed with 1 mCi 
99m
Tc sulphur-colloid 
marker (120 g egg beater, 60 kcal), two slices of bread (120 kcal), strawberry jam (30 
g, 74 kcal), and water (120 mL); total caloric value of 255 kcal (72% carbohydrate, 
24% protein, 2% fat and 2% fibre) 
25
; in meal protocol 2, subjects first ingested a 262-
kcal nutrient bar (SmartBar; Medtronic), modeled on the eggbeater meal, composed 
of 66% carbohydrate, 17% protein, 2% fat, and 3% fiber with 50 mL of water, 
followed by the WMC 
26
. The rationale for reversing the order of meal and capsule 
ingestion was to preclude the possibility of very rapid emptying of the capsule from 
the stomach that was observed in a small minority of clinical studies using protocol 
1; in these cases, the WMC was likely ejected from the stomach during ‘fasted’ 
motor activity (characterized by the migrating motor complex: MMC), prior to 
conversion to a ‘fed’ motility state following meal ingestion. All subjects were then 
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observed for at least 6 hours, during which they were not allowed to eat or sleep. At 
6 hours post-ingestion, they were fed a second standardized meal (250 ml Ensure; 
Abbott Laboratories, Abbott Park, USA). Throughout each study, radiofrequency 
signals emitted by the capsule were recorded on a receiver that was worn 
continuously for 5 days, or until the capsule had been expelled by defecation 
25, 26
. 
 
WIRELESS MOTILITY CAPSULE DATA ANALYSIS 
WMC data for each subject were uploaded to a dedicated computer (Dell, Bracknell, 
UK), and analyzed manually by at least 2 of 3 investigators (YTW, SDM or NZ), with 
discrepancies resolved by consensus (involving SMS).  
REGIONAL TRANSIT TIMES 
Regional transit times were based on clear identification of the following 
stereotypical landmarks, see Figure 1: 
a) time of capsule ingestion (CI) was identified by an abrupt rise in the recorded 
temperature and drop in pH (reflecting passage into the acidic environment 
of the stomach); 
b) exit from the stomach (passage through the pylorus: PY) was identified by an 
abrupt rise in pH of usually more than 3 pH units 
25
; 
c) passage through the ileocecal junction (ICJ) was determined by a drop in pH 
usually of more than 1 pH unit, sustained for at least 10 minutes, occurring at 
least 30 minutes after the capsule had exited the stomach 
26
; 
d) time of WMC expulsion (CE) was determined by an abrupt drop in 
temperature following by loss in recorded signal after the subject had 
defaecated and expelled the WMC. 
 
Based on these landmarks, the following transit times were determined: 
a) GET, defined as the duration between the CI and PY; 
b) small bowel transit time (SBTT), defined as the duration between the PY and 
ICJ; 
c) colonic transit time (CTT), defined as the duration between ICJ and CE; 
d) whole gut transit time (WGTT), defined as the duration between CI and CE; 
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e) combined small bowel transit time and colonic transit time (SBTT+CTT)- 
defined as the duration between PY and CE. 
 
GET, SBTT, CTT and WGTT were also obtained from the automated analysis software 
(MotiliGI), and compared with the corresponding manually obtained data, to 
evaluate the agreement between the 2 methods. 
 
INSERT FIGURE 1 HERE 
Figure 1 – Determination of landmarks and regional transit times on plot data 
obtained from a WMC recording. Blue line: temperature; white line: pH; red line: 
pressure; white arrows: indicate respective points of capsule location; CI: capsule 
Ingestion; PY: pylorus transit; ICJ: ileocecal junction transit; CE: capsule expulsion; 
GET: gastric emptying time; SBTT: small bowel transit time; CTT: colonic transit time. 
 
REGIONAL PH VALUES 
Regional pH values were measured by the following methods: 
a) stomach pH was defined as median pH during GET; 
b) small bowel pH was defined as median pH during SBTT; 
c) colonic pH was defined as median pH during CTT; 
d) pre-expulsion pH was defined as median pH in the final 15 minutes before CE; 
e) delta pylorus was defined as the difference between duodenal (defined as 
median pH in the first 15 minutes after PY) and antral pH (defined as median 
pH during the final 15 minutes prior to expulsion from the stomach); 
f) delta ICJ was defined as the difference between ileal (defined as median pH 
in the final 15 minutes before passage through the ICJ) and cecal pH (defined 
as median pH in the first 15 minutes after ICJ). 
Recordings where pH values were registered as less than 0 at any point were 
considered equipment failures and omitted from further analysis. 
STUDY ENDPOINTS 
The primary study endpoints were GET, SBTT, CTT, WGTT and SBTT+CTT. The 
secondary endpoints were the regional pH values and changes in pH around the 
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pylorus and the ileocecal junction. Effects of meal protocol, gender, age, and study 
country on the transit and pH parameters obtained were examined as exploratory 
endpoints. Agreement between the automated software analysis and manual 
readings of the primary parameters was also evaluated. 
 
STATISTICAL ANALYSIS 
The primary and secondary parameters were summarised using number of 
observations, mean and standard deviation. To assess the impact of meal protocol, 
gender, age and study country on the study endpoints, a multiple linear regression 
model was employed. Reference ranges for the primary and secondary parameters 
were estimated directly from the 5
th
 and 95
th
 percentiles of the measurements. 
Reference ranges were estimated for the combined sample as well as for each 
subgroup according to factors that had a significant effect on the parameters derived 
from multiple linear regression modelling. To compare the agreement between 
automated software analysis and manual reading of primary parameters, a mixed 
model was used to estimate the intra-class correlation coefficient (ICC). The mixed 
model included age, gender and meal protocol as fixed effects, and subject as a 
random effect and interpreted as per Yen et al. 
31
. An ICC of >0.7 suggests good 
agreement between the two types of readings, whereas a value <0.4 indicates poor 
agreement. All statistical analyses were performed using propriety software (SAS, 
version 9.2, SAS Institute Inc., Cary, North Carolina, USA). Two-tailed tests were used 
throughout. P<0.05 was adopted as the statistical criterion.  
 
RESULTS 
PARTICIPANT CHARACTERISTICS 
A total of 231 data files were available. Of these, 16 had major signal loss, meaning 
no regional transit times could be delineated, and were excluded from analysis; most 
of these recordings came from early studies where prototype equipment was used. 
Of the 215 remaining data files, 175 came from studies performed in the USA, and 
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40 came from studies performed in Sweden. Overall, demographic data were missing 
in 20 subjects. CI and PY were identified in all 215 subjects. ICJ could not be 
identified in 16 subjects (7.4%), so SBTT and CTT could not be determined in this 
group. In a further 13 subjects (6.5%), identification of ICJ had to be resolved 
through consensus. In 21 subjects, CE could not be identified due to either a) battery 
failure, or b) expulsion time could not be defined due to signal loss. Summary of 
subject demographics are shown in Table 2. 
 
 
 
Overall 
Country p value 
USA * Sweden  
Meal protocol 
(n) 
1 2 1 2 1 2  
84 128 84 88 0 40 <0.0001 
Gender 
(female : male) 
87:110 
†
 66:91 21:19 NS 
Median age 
(interquartile range) 
‡
 
33 (23-49) 37 (25-53) 23 (22-28) <0.001 
 
Table 2 – Subject demographics. * 3 values missing, 
†
 18 values missing, 
‡ 
20 values 
missing. 
GASTROINTESTINAL TRANSIT TIMES 
Regional GI transit times are presented as the whole group, and as subgroups 
classified by the 2 most significant factors identified from the linear regression 
analysis, i.e. meal protocol and gender, see Table 3. For evaluation of GET relative to 
the test meal, ingestion of a second meal at 6 hours set a ‘ceiling’ at 360 min 
(accordingly, subjects with a GET >6 hours were excluded from GET analysis, but 
included in analysis of other parameters). Overall, 96% of male subjects had expelled 
the capsule before consumption of the second meal, compared to 89% of female 
subjects (although 94% of females using meal protocol 2 had expelled the capsule by 
6 hours). 
Parameter 
Meal 
protocol 
Gender N Mean SD 5
th
 percentile 95
th
 percentile 
Gastric All All 199  3:25 1:01 1:49 5:10 
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emptying 
time * 
1 
F 27 3:53 0:54 2:34 5:25 
M 48 3:45 0:50 2:39 5:18 
2 
F 49 3:20 0:57 1:52 4:58 
M 58 2:54 0:58 1:42 4:53 
Small bowel 
transit time 
All All 199 4:27 1:41 2:17 7:36 
1 
F 32 4:30 1:35 2:04 7:32 
M 46 4:38 1:43 2:30 7:36 
2 
F 50 4:55 2:15 2:16 8:42 
M 54 4:07 1:02 2:26 5:45 
Colonic transit 
time 
All All 182 23:08 15:45 3:26 50:32 
1 
F 30 24:20 17:13 2:26 59:09 
M 43 17:50 11:46 2:20 36:26 
2 
F 45 25:20 14:13 7:28 49:37 
M 50 22:44 16:02 4:19 50:32 
Small bowel 
transit time + 
Colonic transit 
time 
All All 194 27:48 16:06 6:45 62:59 
1 
F 30 28:56 17:19 6:27 64:22 
M 45 22:04 12:02 5:26 41:41 
2 
F 49 30:33 14:51 10:13 65:29 
M 55 27:23 16:32 6:46 62:59 
Whole gut 
transit time 
All All 194 32:12 16:37 9:44 67:51 
1 
F 30 33:57 16:42 8:50 70:41 
M 45 26:54 12:46 9:12 46:42 
2 
F 49 35:23 16:33 13:32 72:40 
M 55 30:40 16:46 10:26 65:28 
 
Table 3 – Normative data for whole and regional GI transit times (hours : minutes). * 
values are relative to the initial test meal.  all values >6 hours excluded (n = 16), as 
second meal given at this time. M = male, F = female. 
 
WGTT and also CTT showed an interesting clustering of data at values separated by 
24 hours, see Figure 2, rather than being distributed normally, as has been presented 
previously 
13
. As shown in Figure 2, nearly 50% of CE occurred around 24 hours after 
capsule ingestion, with a second peak (comprising another 17%) occurring at 48 
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hours. 
 
INSERT FIGURE 2 HERE 
Figure 2 – Frequency polygon of whole gut transit time (WGTT) in hours. WGTT: 
whole gut transit time. Frequency: percentage of WMCs expelled. 
 
EFFECT OF TESTING PROTOCOL, GENDER, AGE AND STUDY COUNTRY ON TRANSIT 
TIMES 
Linear regression analyses demonstrated that meal protocol 2 (WMC ingested after 
the meal) was associated with a shorter GET (p=0.0063), but longer CTT and also 
SBTT+CTT (p=0.0189 and p=0.0307, respectively). There was no overall effect of meal 
protocol on WGTT (p=0.06). Female gender did not influence SBTT, but was 
associated with significantly longer GET (p=0.0307), CTT (p=0.0285), SBTT+CTT 
(p=0.0195) and WGTT (p=0.0077). Increasing age was associated with shorter SBTT 
(p=0.002). Studies performed in Sweden were associated with longer SBTT 
(p=0.0019), but shorter CTT (p=0.0263). 
 
AGREEMENT BETWEEN MANUAL AND AUTOMATED RESULTS 
The agreement between regional GI transit times determined manually and those 
obtained by the automated software, as expressed as intra-class correlation 
coefficients, were 0.98 for GET, 0.54 for SBTT, 0.93 for CTT and 0.91 for WGTT. 
 
 
GASTROINTESTINAL pH; EFFECT OF MEAL PROTOCOL, GENDER AND AGE  
Normative values for regional GI pH measurements are presented in Table 4. Meal 
protocol was statistically significantly associated with a difference in pH in the 
stomach (higher with protocol 2: p<0.0001), and with changes in pH recorded across 
the pylorus and also the ICJ (smaller magnitude of change for both delta pylorus and 
delta ICJ with protocol 2: p=0.0055 and p=0.009, respectively). Gender differences 
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significantly influenced pH (female higher in both cases) in the small bowel 
(p=0.0177) and 15 minutes prior to capsule expulsion (p=0.0117). Age had no effect 
on pH. Studies performed in Sweden were associated with an overall lower pH in the 
stomach (p<0.0001), small bowel (p=0.0104) and colon (p=0.0004), and also a 
smaller magnitude of change for delta ICJ (p=0.0125). 
 
 
Parameter 
Meal 
protocol 
Gender N Mean SD 5
th
 percentile 95
th
 percentile 
Gastric pH 
All All 205 1.9 1.3 0.7 4.6 
1 
F 30 1.5 0.5 0.7 2.7 
M 45 1.2 0.8 0.7 1.7 
2 
F 54 2.1 1.5 0.7 4.9 
M 58 2.2 1.4 0.5 5.1 
Small bowel 
pH 
All All 198 7.2 0.5 6.3 7.8 
1 
F 30 7.3 0.5 6.3 8.0 
M 41 7.2 0.4 6.4 7.8 
2 
F 54 7.2 0.4 6.5 7.9 
M 56 7.0 0.6 6.2 7.7 
Colonic pH 
All All 182 7.0 0.8 5.7 8.1 
1 
F 27 7.2 0.8 5.8 8.7 
M 38 7.1 0.8 6.0 9.0 
2 
F 51 6.9 0.8 5.5 8.1 
M 53 6.8 0.7 5.3 7.6 
Delta pylorus 
All All 201 5.1 0.7 4.1 5.8 
1 
F 29 5.2 0.5 4.1 6.0 
M 44 5.2 0.8 4.0 6.0 
2 
F 54 5.0 0.6 4.0 5.7 
M 57 5.0 0.5 4.2 5.7 
Delta ICJ 
All All 186 1.2 0.5 0.3 2.1 
1 
F 28 1.4 0.4 0.8 2.1 
M 42 1.5 0.5 0.7 2.2 
2 F 50 1.2 0.5 0.4 2.0 
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M 51 1.1 0.6 0.2 1.9 
15 minutes 
pre expulsion 
All All 176 7.3 0.9 6.0 8.7 
1 
F 24 7.7 1.0 5.8 9.5 
M 37 7.4 1.0 6.2 10.0 
2 
F 49 7.3 1.1 6.1 9.0 
M 53 7.0 0.7 5.8 8.0 
 
Table 4 - Normative WMC data for regional GI pH values. M = male, F = female. 
 
DISCUSSION 
To date, this is the largest reported data set that explores pan-gastrointestinal and 
regional GI transit times in healthy humans. GI transit times measured by the WMC 
have previously been shown to correlate strongly with those of other established 
methods of investigation 
17, 25, 26, 32, 33
. The current study presents robust evidence 
that the testing protocol, gender, age and study country influence regional GI transit 
times (and also intraluminal pH), and therefore should be taken into consideration 
when interpreting data in a clinical context. However, as a broad benchmark, the 
data presented herein demonstrates that if the WMC is not expelled by the 3
rd
 
morning after ingestion (i.e. 72 hours), transit through the whole gut (and at least 1 
region of the GI tract) is pathologically delayed. 
 
As the WMC is an indigestible solid, its expulsion from the stomach is facilitated by 
distally propagating high amplitude antral contractions from phase III of the 
migrating motor complex 
34
. This pattern occurs in the fasting state, so expulsion of 
WMC from the stomach is dependent on cessation of “fed state” stomach 
contractions, associated with the initial test meal 
30
. The study protocol employed 
included resetting the fed state by feeding subjects a second meal at 6 hours, which 
would impede the expulsion of capsules retained in the stomach at this time. This is 
supported by the observation that of the 15 subjects (6.9% overall: 11 females) with 
a GET >6 hours, 11/15 (73%) did not expel the WMC from the stomach for in excess 
of 3 hours after their second meal (which reset the “fed state”), while the remaining 
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4 subjects all emptied within the first 20 minutes of the second meal (before 
initiation of the “fed state”). Therefore, only a GET of less than 6 hours is clinically 
relevant, and indeed, previous studies have ‘capped’ the upper limit of GET at 6 
hours 
25, 26
. For meal protocol 2 (test meal consumed prior to swallowing the capsule, 
which is now the recommended standard protocol in clinical use 
5
), male subjects 
had a measurable upper limit for GET of approximately 5 hours. For females 
following meal protocol 2, 87% had expelled the capsule from their stomach by 5 
hours, in agreement with the boundary proposed from the original study 
25
, and 94% 
had done so by 6 hours.  
 
The data presented in the current study agrees with previous studies that have 
shown a shorter GET when subjects consumed the meal before capsule ingestion 
(meal protocol 1) 
25, 32
. In such subjects, recording of GET began approximately 15 
minutes before conversion into the fed state by the test meal. Conversely, in 
subjects who ingested the meal first (protocol 2), gastric contractility would have 
already been converted into the fed state prior to the start of the WMC recording. 
This is the cause of the statistically significant difference in overall median GET 
between the study protocols of 52 minutes. Indeed, from early clinical studies 
employing meal protocol 1, it was observed that gastric expulsion of the WMC was 
extremely rapid in a small number of subjects (within 5 minutes of capsule ingestion: 
data supplied by SmartPill Corporation); for this reason, adoption of meal protocol 2 
(consuming the standard test meal (SmartBar) prior to ingesting the WMC), as well 
as restriction from a second meal for at least 6 hours after the study commences, is 
now recommended. These results further highlight the need for a standardised 
protocol to enable valid cross-referencing of data. 
 
Overall, regional transit times were generally longer in females, mirroring previous 
observations 
26, 35-38
. For example, Sadik et al. demonstrated in a study of 83 healthy 
controls, using a combination technique of ROM and fluoroscopy, that gastric 
emptying, small-bowel transit and colonic transit were significantly slower in females 
20
. The menstrual cycle per se may also influence GI transit, for example, Wald et al. 
reported that GI transit time was prolonged in the luteal phase of the menstrual 
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cycle in comparison to the follicular phase, thereby implying an effect of rising 
progesterone on retarding transit 
39
. Nevertheless, these data and ours highlight the 
importance of refining reference ranges particularly by gender, but there is a similar 
argument also to do so by BMI, stage of the menstrual cycle and menopausal status. 
Indeed, a limitation of our study is that we did not collect data on menstrual cycle 
and status, although we did exclude subjects with a BMI in excess of 35 kg/m
2
. 
Variations in small bowel and colonic transit times were also seen between 
countries, though these results should be interpreted with caution as only 18.6% of 
recordings (40 of 215) were from Sweden. Nevertheless we postulate that host, 
environmental, and particularly dietary differences between Sweden and the USA, 
which are known to influence gut microbiota 
40
, metabolites 
41
 and consequently 
motility 
42
, may account for some of these differences. This is supported by 
differences in regional luminal pH seen between study countries (gut pH more acidic 
in the Swedish population). 
 
One striking finding of this study was that WGTT (and CTT) showed an interesting 
clustering of data at values separated by 24 hours (see Figure 2). These frequency 
peaks appeared to be the result of capsule expulsion with the first bowel movement 
of the day. It is known that both morning waking and meal consumption result in an 
increase in colonic contractile activity 
43
, with the combined effect of both of these 
physiological stimuli thereby producing strong colonic contractions which precede 
defecation; accordingly, CE is most likely to occur in this period. This finding is of 
major importance with regard to the performance of current ROM techniques. Given 
that the data presented in this study show that whole gut (and also colonic) transit 
cannot be described as a continuous variable (as promoted by several existing 
methods) 
35, 44
, we propose that a more physiological way to report whole gut (and 
colonic) transit time(s) is as increments of 24 hours. Our data demonstrated that 
36% of subjects expelled the capsule by 24 hours, 85% by 48 hours, and 96% by 72 
hours. Such an approach requires subjects to commence the investigation at the 
same time of the day, which is now the recommended protocol, see Table 5. It would 
also be desirable, though clearly impractical, to standardise meal composition 
throughout the study period (and perhaps for a couple of days prior to the start of 
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the test also). Lack of standardisation remains a major limitation with almost all 
other contemporary tests of GI function, especially those involving radiology, where 
scheduling conflicts presents a logistical challenge to establishing a common 
ingestion time. The lack of use of standardized meals and scan times also continues 
to be problematic. In contrast to other motility testing, with the exception of high-
resolution esophageal manometry 
45
, the WMC offers uniformity of test 
administration and interpretation. Despite these advantages, the intra-individual 
reproducibility of the WMC remains to be fully determined. 
 
 
Standardized Wireless Motility Testing Protocol 
1 Overnight fast 
2 Record subject details 
 a. age 
b. gender 
c. BMI 
3 Discontinue use of medications 
 a. proton pump inhibitors for 7 days prior to, and throughout study period 
b. histamine-2 receptor antagonists for 3 days prior to, and throughout study 
period 
c. antacids stopped for 1 day prior to, and throughout study period 
d. prokinetics for 3 days prior to, and throughout study period 
e. laxatives for 2 days prior to, and throughout study period 
4 Commence test in the morning 
 a. consume SmartBar®, or “eggbeater” meal 
 b. ingest WMC as soon as meal is completed 
5 Standardised meal 6 hours after WMC ingestion 
6 No standardisation of meals thereafter, with subjects instructed to follow their 
‘normal eating habits’ 
7 Record eating habits (including meal constituents), symptoms, periods of sleep, and 
bowel movements in a patient diary 
8 Download recorded data to PC for analysis 
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Table 5 – Proposed standardized test protocol. 
 
The United States Food and Drug Administration have approved the WMC for the 
measurement of GET in those patients in whom gastroparesis is suspected, the 
evaluation of CTT in patients with suspected slow transit constipation, and the 
measurement of pH, pressure and temperature throughout the GI tract. The 
American and the European Neurogastroenterology and Motility Societies have 
endorsed these indications in a recently published position paper 
46
. Within these 
endorsed indications, the current upper limit of normal for GET is 5 hours 
47
. We 
agree with the original investigators who optimized the cut-off for clinical utility in 
these populations, and thus we would advocate not redefining this value. 
 
With regard to regional pH values, in vivo data on the pH profile throughout the gut 
were first described in 1972 
48
. The use of pH changes to determine transition from 
stomach to small bowel (transit across the pylorus) and from small bowel to large 
bowel (movement across the ileocecal junction) has since been validated 
49-52
. In the 
current study, PY was identified in all subjects, but determination of ICJ was not 
possible in 16 subjects, as there were no clear pH drop. It is possible that excluding 
these data introduced a degree of bias, although we would argue that, if indeed 
present, it would be small given that these 16 subjects made up only 7.4% of the 
cohort. Although the method of identifying ICJ transition has recently been verified 
52
, it was recognised that the drop in pH occurred a median of 7 minutes after 
passage through the ICJ and that there is variability in the magnitude and 
morphology of this drop. Such variations have been attributed to ileocecal valve 
incompetence or variation in acidity in the right colon created by metabolite 
production (e.g. short-chain fatty acids) through bacterial fermentation 
53-55
. In the 
event that the ICJ cannot be identified, SBTT+CTT can be used as a surrogate to 
diagnose delayed transit 
33
. Abnormalities in intraluminal pH may feasibly represent 
alterations in gut microbiota 
56
. A recent paper by Farmer et al. reported differences 
in both cecal pH and delta ICJ pH in IBS patients compared to healthy controls 
55
. The 
authors concluded that these measures, as recorded by the WMC, may represent 
quantifiable surrogate biomarkers of fermentation, potentially identifying those 
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patients that may preferentially benefit from antibiotic or dietary interventions 
55
. 
Furthermore, this metric may potentially provide further insight into the mechanism 
of action of probiotics in the treatment of IBS 
56
. A further interesting potential of 
this technology is in evaluating both the changes in motility and surrogate changes in 
fermentation in response to the nascent therapeutic area of faecal microbiota 
transplantation 
57
.  
 
When testing agreement between manual and automated analysis, the former was 
taken as the ‘gold standard’. Stereotypical pH changes around the pylorus and ICJ 
are readily appreciated qualitatively (100% and 93% respectively), but subtle (and 
morphologically variable) pH changes across the ICJ are poorly identified by the 
automated software analysis, which resulted in SBTT being significantly different 
from that identified manually (ICC = 0.54). While this also affected CTT, the longer 
time period of CTT meant that the difference was of a much smaller magnitude. In 
contrast, the large (and morphologically less variable) pH change across the pylorus 
was reliably identified by the automated software, which is reflected by a high 
degree of agreement (0.98) with the manually obtained value. At the present time, 
we would advocate manual verification of the fall in pH around the ICJ (which is 
indeed prescribed by the device software), as the automatic algorithm is sub-optimal 
and warrants refinement. Notably, the pH drop was <1.0 pH unit in 52 subjects 
(26%), which is in contrast to the defining criterion of “usually of more than 1 pH 
unit” 
26,48
; this needs to be allowed for. 
 
As with regional transit times, testing protocol significantly influenced pH values in 
the stomach and also the magnitude of pH change across the pylorus and ICJ, again 
supporting the need for a standardised protocol to be adopted. Female gender also 
significantly influenced both small bowel pH, and pH in the distal large bowel, which 
may be allied to sex differences in gut microbiota. The clinical importance of this 
finding is unclear.  
 
In conclusion, the WMC is an ambulatory, minimally invasive, and non-radiological 
method for determining whole and regional GI transit times and pH. We have 
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demonstrated that in healthy subjects, both transit and pH are influenced by gender, 
age, testing protocol and country where the study is performed. Normative values 
for regional transit times and delta ICJ are presented for reference in clinical 
practice, see Table 6. 
 
 Accelerated 
Transit 
(hours:min) 
Delayed  
Transit 
(hours:min) 
 
GET 
 
 <1:45 
 
>5:00 * 
 
 
SBTT 
 
 <2:15 >8:00 
US  <2:15  >6:00 
Sweden  <3:30  >8:45 
CTT 
 <5:00 >50:30 
US  <4:30  >58:45 
Sweden  <5:00  >39:30 
 
SBTT+CTT 
 
 <8:15 
 
>65:15 
 
 
WGTT 
 
 <10:45 >68:45 † 
 
Decreased 
(ΔpH) 
Increased 
(ΔpH) 
 
Delta ICJ 
 
 <0.4 
 
>2.0 
 
 
Table 6 – Simplified table of normative cut-offs for both accelerated and delayed GI 
transit and pH change across the ICJ for use in clinical practice. 
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For ease of clinical use, transit time values rounded-up to the nearest 15 min 
* proposed cut-off based on 87
th
 percentile 
†
 cut-off alternatively described as >3 days after ingestion; data show WGTT is a non-
continuous variable
 
 
REFERENCES 
1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper 
gastrointestinal diseases. Gastroenterology 2009;136(2):376-86. 
2. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower 
gastrointestinal diseases. Gastroenterology 2009;136(3):741-54. 
3. Sadik R, Stotzer PO, Simren M, Abrahamsson H. Gastrointestinal transit abnormalities are 
frequently detected in patients with unexplained GI symptoms at a tertiary centre. 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 
Motility Society 2008;20(3):197-205. 
4. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR. Lower functional 
gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 
Motility Society 2010;22(3):293-e82. 
5. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: 
position paper of the American and European Neurogastroenterology and Motility Societies. 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 
Motility Society 2011;23(1):8-23. 
6. Zarate N, Knowles CH, Yazaki E, Lunnis PJ, Scott SM. Clinical presentation and patterns of slow 
transit constipation do not predict coexistent upper gut dysmotility. Digestive diseases and 
sciences 2009;54(1):122-31. 
7. Bonapace ES, Maurer AH, Davidoff S, Krevsky B, Fisher RS, Parkman HP. Whole gut transit 
scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal 
symptoms. Am J Gastroenterol 2000;95(10):2838-47. 
8. Camilleri M, Bharucha AE, di Lorenzo C, et al. American Neurogastroenterology and Motility 
Society consensus statement on intraluminal measurement of gastrointestinal and colonic 
motility in clinical practice. Neurogastroenterology and motility : the official journal of the 
European Gastrointestinal Motility Society 2008;20(12):1269-82. 
9. Bouras EP, Burton DD, Camilleri M, Stephens DA, Thomforde GM. Effect of cyclooxygenase-2 
inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroenterology and 
motility : the official journal of the European Gastrointestinal Motility Society 2004;16(6):729-35. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
10. Camilleri M, Iturrino J, Bharucha AE, et al. Performance characteristics of scintigraphic 
measurement of gastric emptying of solids in healthy participants. Neurogastroenterology and 
motility : the official journal of the European Gastrointestinal Motility Society 2012. 
11. Dinning PG, Smith TK, Scott SM. Pathophysiology of colonic causes of chronic constipation. 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 
Motility Society 2009;21 Suppl 2:20-30. 
12. [Measurement of colonic transit time (total and segmental) with radiopaque markers. National 
reference values obtained in 192 healthy subjects. Spanish Group for the Study of Digestive 
Motility]. Gastroenterologia y hepatologia 1998;21(2):71-5. 
13. Evans RC, Kamm MA, Hinton JM, Lennard-Jones JE. The normal range and a simple diagram for 
recording whole gut transit time. International journal of colorectal disease 1992;7(1):15-7. 
14. Bouchoucha M, Devroede G, Dorval E, Faye A, Arhan P, Arsac M. Different segmental transit 
times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a 
correlation with symptoms? Techniques in coloproctology 2006;10(4):287-96. 
15. Danquechin Dorval E, Barbieux JP, Picon L, Alison D, Codjovi P, Rouleau P. [Simplified 
measurement of colonic transit time by one radiography of the abdomen and a single type of 
marker. Normal values in 82 volunteers related to the sexes]. Gastroenterologie clinique et 
biologique 1994;18(2):141-4. 
16. Chan YK, Kwan AC, Yuen H, et al. Normal colon transit time in healthy Chinese adults in Hong 
Kong. Journal of gastroenterology and hepatology 2004;19(11):1270-5. 
17. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: 
establishment of international control values. The American journal of gastroenterology 
2000;95(6):1456-62. 
18. Hellmig S, Von Schoning F, Gadow C, et al. Gastric emptying time of fluids and solids in healthy 
subjects determined by 13C breath tests: influence of age, sex and body mass index. Journal of 
gastroenterology and hepatology 2006;21(12):1832-8. 
19. Miller MA, Parkman HP, Urbain JL, et al. Comparison of scintigraphy and lactulose breath 
hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. 
Digestive diseases and sciences 1997;42(1):10-8. 
20. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly 
developed radiological procedure. Scand J Gastroenterol 2003;38(1):36-42. 
21. Medhus AW, Lofthus CM, Bredesen J, Husebye E. Gastric emptying: the validity of the 
paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterol Motil 
2001;13(3):179-85. 
22. Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for 
abnormal gastric emptying of solids in the clinic and in research. Clinical gastroenterology and 
hepatology : the official clinical practice journal of the American Gastroenterological Association 
2008;6(6):635-643 e1. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
23. La Brooy SJ, Male PJ, Beavis AK, Misiewicz JJ. Assessment of the reproducibility of the lactulose 
H2 breath test as a measure of mouth to caecum transit time. Gut 1983;24(10):893-6. 
24. Darwiche G, Almer LO, Bjorgell O, Cederholm C, Nilsson P. Measurement of gastric emptying by 
standardized real-time ultrasonography in healthy subjects and diabetic patients. Journal of 
ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 
1999;18(10):673-82. 
25. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule 
to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther 
2008;27(2):186-96. 
26. Rao SS, Kuo B, McCallum RW, et al. Investigation of colonic and whole-gut transit with wireless 
motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol 
2009;7(5):537-44. 
27. Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal 
reflux disease. Mayo Clinic proceedings. Mayo Clinic 1994;69(6):539-47. 
28. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. 
Journal of gastrointestinal and liver diseases : JGLD 2006;15(3):237-41. 
29. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in 
patients with irritable bowel syndrome and peptic ulcer disease. Digestive diseases and sciences 
1988;33(2):129-34. 
30. Cassilly D, Kantor S, Knight LC, et al. Gastric emptying of a non-digestible solid: assessment with 
simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying 
scintigraphy. Neurogastroenterology and motility : the official journal of the European 
Gastrointestinal Motility Society 2008;20(4):311-9. 
31. Yen M, Lo LH. Examining test-retest reliability: an intra-class correlation approach. Nurs Res 
2002;51(1):59-62. 
32. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill 
GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci 
2009;54(10):2167-74. 
33. Camilleri M, Thorne NK, Ringel Y, et al. Wireless pH-motility capsule for colonic transit: 
prospective comparison with radiopaque markers in chronic constipation. 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 
Motility Society 2010;22(8):874-82, e233. 
34. Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. 
Gastroenterology 1984;86(6):1592-610. 
35. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment 
of segmental colonic transit. Gastroenterology 1987;92(1):40-7. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
36. McLean RG, Smart RC, Lubowski DZ, King DW, Barbagallo S, Talley NA. Oral colon transit 
scintigraphy using indium-111 DTPA: variability in healthy subjects. International journal of 
colorectal disease 1992;7(4):173-6. 
37. Bennink R, Peeters M, Van den Maegdenbergh V, et al. Evaluation of small-bowel transit for solid 
and liquid test meal in healthy men and women. European journal of nuclear medicine 
1999;26(12):1560-6. 
38. Malagelada JR, Robertson JS, Brown ML, et al. Intestinal transit of solid and liquid components of 
a meal in health. Gastroenterology 1984;87(6):1255-63. 
39. Wald A, Van Thiel DH, Hoechstetter L, et al. Gastrointestinal transit: the effect of the menstrual 
cycle. Gastroenterology 1981;80(6):1497-500. 
40. Kashyap PC, Marcobal A, Ursell LK, et al. Complex interactions among diet, gastrointestinal 
transit, and gut microbiota in humanized mice. Gastroenterology 2013;144(5):967-77. 
41. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their 
FODMAP content alter the colonic luminal microenvironment. Gut 2015;64(1):93-100. 
42.  Reigstad CS, Salmonson CE, Rainey JF 3rd, et al. Gut microbes promote colonic serotonin 
production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 
2015;29(4):1395-403. 
43. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. Prolonged multi-point recording of 
colonic manometry in the unprepared human colon: providing insight into potentially relevant 
pressure wave parameters. The American journal of gastroenterology 2001;96(6):1838-48. 
44. Abrahamsson H, Antov S, Bosaeus I. Gastrointestinal and colonic segmental transit time 
evaluated by a single abdominal x-ray in healthy subjects and constipated patients. Scandinavian 
journal of gastroenterology. Supplement 1988;152:72-80. 
45. Bredenoord AJ, Fox M, Kahrilas PJ, et al. Chicago classification criteria of esophageal motility 
disorders defined in high resolution esophageal pressure topography. Neurogastroenterology 
and motility : the official journal of the European Gastrointestinal Motility Society 2012;24 Suppl 
1:57-65. 
46. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: 
position paper of the American and European Neurogastroenterology and Motility Societies. 
Neurogastroenterol Motil 2011;23(1):8-23. 
47. Stein E, Berger Z, Hutfless S, et al. In: Wireless motility capsule versus other diagnostic 
technologies for evaluating gastroparesis and constipation: a comparative effectiveness review. 
Rockville (MD); AHRQ Comparative Effectiveness Reviews. 2013. 
48. Watson BW, Meldrum SJ, Riddle HC, Brown RL, Sladen GE. pH profile of gut as measured by 
radiotelemetry capsule. Br. Med. J. 1972;2(5805):104-6. 
49. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal 
pH profiles in normal ambulant human subjects. Gut 1988;29(8):1035-41. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
50. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on 
ileal and colonic pH as measured by a radiotelemetry device. Gut 1974;15(12):999-1004. 
51. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. 
pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. 
Alimentary pharmacology & therapeutics 1989;3(6):605-13. 
52. Zarate N, Mohammed SD, O'Shaughnessy E, et al. Accurate localization of a fall in pH within the 
ileocecal region: validation using a dual-scintigraphic technique. Am J Physiol Gastrointest Liver 
Physiol 2010;299(6):G1276-86. 
53. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the 
human colon. The Journal of applied bacteriology 1991;70(6):443-59. 
54. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different 
regions of the human colon. The Journal of applied bacteriology 1992;72(1):57-64. 
55. Farmer AD, Mohammed SD, Dukes GE, Scott SM, Hobson AR. Caecal pH is a biomarker of 
excessive colonic fermentation. World J Gastroenterol 2014;20(17):5000-7. 
56. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome 
foundation report. Gut 2013;62(1):159-76. 
57. Ianiro G, Bibbò S, Gasbarrini A, Cammarota G. Therapeutic modulation of gut microbiota: current 
clinical applications and future perspectives. Curr Drug Targets 2014;15(8):762-70. 
 
CONFLICT OF INTEREST/STUDY SUPPORT 
Guarantor of the article:   Dr S Mark Scott, PhD  
 
Specific author contributions:  Yu Tien Wang, Sahar D Mohammed, Natalia 
Zarate: data acquisition, drafting of the 
manuscript. 
 Duolao Wang: statistical analysis. 
Adam D Farmer: drafting of the manuscript; 
statistical analysis; critical revision of the 
manuscript for important intellectual content.  
Anthony R Hobson, Per M Hellström, Jack R 
Semler, Braden Kuo, Satish S Rao, William L 
Hasler, Michael Camilleri, S Mark Scott: Study 
concept and design; acquisition of data; 
statistical analysis; study supervision, critical 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
revision of the manuscript for important 
intellectual content. 
 
Financial support: The healthy control research was supported by 
a grant from the SmartPill Corporation.  
 
Potential competing interests:  Professor Camilleri previously served as a 
consultant to SmartPill Corporation, with 
compensation to the Mayo Clinic, not to him.  
Drs Scott, Kuo and Hasler, and Professors Rao 
and Hellström previously received grant funding 
from the SmartPill Corporation. 
Dr Semler is an employee of Medtronic.  
Dr Hobson was a paid instructor for Given 
Imaging.  
Au
th
or
 M
an
us
cr
ip
t
apt13329-fig-0001.png
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
apt13329-fig-0002.jpg
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
